(audio-EN) Gladius Pharmaceuticals closes a $4,1 million Series A for its new generation of antibiotics
Montreal (QUEBEC) – After a year of negotiations, the newly created company Gladius Pharmaceuticals has successfully raised $4,1 million in a Series A financing. In this interview, Michael Atkin, CEO of Gladius, explains how he got in touch with the prestigious investors that participated in the operation, including Lumira Capital, SR One and Fonds de solidarité FTQ. He also explains he will use these new resources to fund preclinical studies with its lead compound. Gladius develops a new type of antibiotics with a dual mechanism that combines antibiotic functionality with activity against beta-lactamase inhibition.